Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China State Council Lines Up Tasks In Five Key Healthcare Reforms

This article was originally published in PharmAsia News

Executive Summary

China's General Office of the State Council recently released the tasks identified for five key healthcare reforms in 2009: speed up establishment of a basic medical care system; set up a national essential drug system; improve the grassroots medical care service system; promote uniformity in basic public healthcare; and push for reform pilots in public hospitals. According to the line-up of requirements, the national essential drug list is to be finalized by the end of November, with all drugs included in the drug catalog of the national basic medical insurance. Public hospital reform pilots will be conducted in about 100 hospitals of 12 prefecture cities identified from the Eastern, Central and Western regions of China. The State Council task force, which leads the deepening of the healthcare reform, will inspect the overall implementation by year end. (Click here for more - Chinese language)

You may also be interested in...



Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

Epizyme’s Tazverik Gets To Market In Rare Sarcoma, Paving Way To Bigger Indications

Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.

UsernamePublicRestriction

Register

SC072300

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel